<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268280</url>
  </required_header>
  <id_info>
    <org_study_id>CY 4023</org_study_id>
    <secondary_id>1RC3NS070670-01</secondary_id>
    <nct_id>NCT01268280</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis</brief_title>
  <official_title>A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Cytokinetics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this early-stage clinical study is to demonstrate an effect of
      single doses of CK-2017357 on measures of skeletal muscle function and fatigability in
      patients with generalized myasthenia gravis (MG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase II, double-blind, randomized, three-way crossover, placebo-controlled,
      PD study of CK-2017357 in patients with generalized MG on standard therapy. 36 to 78 patients
      will be randomized at approximately 15 study centers to one of six different treatment
      sequences. Each treatment sequence consists of three dosing periods in which patients receive
      single oral doses of placebo, 250 mg, and 500 mg of CK-2017357. All six treatment sequences
      will enroll 6 patients. A wash out period of at least 7 days (to a maximum of 10 days) will
      be employed between the individual doses for each patient. This study is designed to assess
      the effects of CK-2017357 on the standardized Quantitative Myasthenia Gravis (QMG) score,
      Manual Muscle Test, Myasthenia Gravis Composite Assessment (MGCA) and Forced Vital Capacity.
      The pharmacokinetic (PK) and pharmacodynamic (PD) relationship of CK-2017357 after two single
      doses will be assessed versus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed after complete treatment of 32 patients after 21 months' recruitment.
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative Myasthenia Gravis score (QMG)</measure>
    <time_frame>1 day</time_frame>
    <description>A quantitative motor assessment of muscular weakness on a scale of 0 to 3 with 0 representing &quot;none&quot; and 3 representing &quot;severe&quot;. Muscular assessments included in the overall score are effects on double vision, ptosis, facial muscles, swallowing, speech, outstretched arms and legs, forced vital capacity, hand grip strength, and ability to lift head.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Test (VC in liters)</measure>
    <time_frame>1 day</time_frame>
    <description>Forced Vital Capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Manual Muscle Test (MMT)</measure>
    <time_frame>1 day</time_frame>
    <description>Sum of strength or function values assessed by physician on the neck, shoulder, hip and ankle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize dose and plasma concentrations of CK-2017357 and QMG</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize dose and plasma concentrations of CK-2017357 and Forced Vital Capacity (FVC)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize dose and plasma concentrations of CK-2017357 and Manual Muscle Test (MMT)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified MG Symptom Score</measure>
    <time_frame>2 days</time_frame>
    <description>Patients will be asked questions regarding five myasthenia gravis systems including trouble using eyes, trouble eating, difficulty speaking, trouble walking and trouble performing personal grooming needs. Each of the areas is scored 0 (none at all) to 3 (very much) and the overall score combining the score of all five areas on a scale of 0 to 15 with 0 being normal and 15 being severe weakness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>2 days</time_frame>
    <description>Patients answer a single question as to whether they feel the same, better or worse as compared to how they felt pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment</measure>
    <time_frame>2 days</time_frame>
    <description>Investigator answer a single as question as to whether they think the patient appears the same, better or worse as compared to the patient's status at pre-dose</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 CK-2017357 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 CK-2017357 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo in capsules administered as a single oral dose.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>250 mg CK-2017357</intervention_name>
    <description>250 mg CK-2017357 in capsules administered as a single oral dose.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
    <other_name>tirasemtiv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg CK-2017357</intervention_name>
    <description>500 mg CK-2017357 in capsules administered as a single oral dose.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
    <other_name>tirasemitiv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Ability to comprehend and willing to sign an Informed Consent Form (ICF)

          -  Ability to understand written and oral English language

          -  Males and females between 18 and 80 years of age, inclusive

          -  Patient's signs and symptoms not better explained by another disease process

          -  Established diagnosis of MG defined as clinical evidence of muscle weakness and
             positive AChR-binding antibody titer (&gt;0.02 nmol/L)

          -  Myasthenia Gravis Foundation of America (MGFA) clinical classification II or III

          -  Stable MG disease for 4 weeks prior to randomization

          -  Ability to refrain from IVIg treatments during the course of the study

          -  Ability to refrain from cholinesterase-inhibitors (e.g. pyridostigmine) for 12 hours
             before each dose

          -  Ability to perform all elements of the QMG

          -  Grade of 2 or 3 in two or more of the following muscle groups as measured by QMG:
             right or left arm flexion, head lift, and right or left leg raise at 45Â° Note:
             Patients may re-screen if they fail due to inadequate weakness from taking
             pyridostigmine within 12 hours of screening

          -  Body mass index (BMI) of 18.0 to 36.0 kg/m2, inclusive

          -  Pre-study clinical laboratory findings (including troponin I [TnI] and creatine
             phosphokinase [CPK]) within the normal range, or if outside of the normal range,
             deemed not clinically significant by the Investigator

          -  For female patients only: Agreement to use a double barrier during sexual intercourse
             (1 hormonal, plus 1 barrier method, or 2 simultaneous barrier methods) birth control
             (birth control pills, male condom, female condom, intrauterine device, Norplant, tubal
             ligation, or other sterilization procedures)

          -  For male patients only: Agreement either to use a condom during sexual intercourse
             with female partners who are of reproductive potential and to have female partners use
             an additional effective means of contraception (e.g., diaphragm plus spermicide, or
             oral contraceptives) for the duration of the study and 10 weeks after the end of the
             study or to abstain from sexual intercourse for the duration of the study and 10 weeks
             after the end of the study

        Exclusion criteria:

          -  History of chronic degenerative, psychiatric, or neurologic disorder other than MG
             that can produce weakness or fatigue

          -  Other major chronic or debilitating illnesses within six months prior to study entry

          -  Hepatic insufficiency (defined as ALT or AST &gt; 3x ULN, or total bilirubin &gt; 3 mg/dL)

          -  Renal insufficiency (defined as serum creatinine &gt; 2.5 mg/dL or receiving dialysis)

          -  Other myasthenic syndromes (e.g. Lambert Eaton syndrome; inherited myasthenic
             syndrome)

          -  Female patients who are premenopausal and are: (a) pregnant on the basis of a serum
             pregnancy test, (b) breast-feeding, or (c) not using an effective method of double
             barrier (1 hormonal plus 1 barrier method or 2 simultaneous barrier methods) birth
             control (birth control pills, male condom, female condom, intrauterine device,
             Norplant, tubal ligation, or other sterilization procedures)

          -  Receipt of IVIg or plasmapheresis treatment within 6 weeks prior to the first dose of
             study drug

          -  Changes to immunosuppressive treatments (i.e., prednisone) within 6 weeks prior to the
             first dose of study drug

          -  Rituxan treatment within 3 months prior to study entry

          -  Participation in any other investigational study drug or device trial in which receipt
             of an investigational study drug or device occurred within 30 days prior to dosing

          -  Any prior treatment with CK-2017357

          -  Recent history of alcoholism or drug abuse, or significant behavioral or psychiatric
             problems, or other conditions which in the Investigator's opinion may impair ability
             to adequately comply with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Wolff, MD, FACC</last_name>
    <role>Study Director</role>
    <affiliation>Cytokinetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF - Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocare Center for Research</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Penn Allegheny Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sanders DB, Rosenfeld J, Dimachkie M, Meng L, Malik FI. A Study to Evaluate Efficacy, Safety and Tolerability of Single Doses of Tirasemtiv in Patients with Myasthenia Gravis. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 2013</citation>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>December 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2010</study_first_posted>
  <disposition_first_submitted>September 18, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 18, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 24, 2019</disposition_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

